Zions Bancorporation N.A. Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Zions Bancorporation N.A. increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 97.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,639 shares of the company's stock after purchasing an additional 18,104 shares during the quarter. Zions Bancorporation N.A.'s holdings in Novo Nordisk A/S were worth $3,152,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $28,000. Center for Financial Planning Inc. grew its stake in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Dunhill Financial LLC raised its holdings in Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company's stock valued at $56,000 after acquiring an additional 311 shares during the last quarter. Albion Financial Group UT lifted its stake in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $46,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NVO. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average price target of $145.25.

Remove Ads

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $0.81 during midday trading on Friday, hitting $69.36. The company had a trading volume of 5,852,065 shares, compared to its average volume of 5,563,763. The stock has a market cap of $311.23 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company's 50 day simple moving average is $82.33 and its 200 day simple moving average is $99.11. Novo Nordisk A/S has a 52-week low of $69.18 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.